Lonza and Genetix Extend Manufacturing Agreement for ZYNTEGLO™

Lonza Group AG and Genetix Biotherapeutics Inc. have extended their commercial manufacturing agreement, essential for meeting the increasing demand for ZYNTEGLO™. This gene therapy, primarily for beta-thalassemia patients, has been FDA-approved for both children and adults who rely on regular transfusions.

The collaboration, originating in 2013, facilitated the commercial approval of ZYNTEGLO™ in 2022. The latest agreement ensures continued manufacturing at Lonza's Houston facility, which specializes in cell and gene therapy. This site will meet the current demand and is poised for future scalability of additional therapies from Genetix.

Lonza emphasizes the agreement’s role in reinforcing their capabilities in delivering gene therapy solutions. Genetix highlights the partnership's importance in consistently providing therapies, underscoring their commitment to meeting patient needs and expanding manufacturing infrastructure.